QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dmd.105.008201v1 34/9/1443    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, X. Articles by Van Deusen, J. Search for Related Content PubMed PubMed Citation Articles by Liu, X. Articles by Van Deusen, J.

SHORT COMMUNICATION

Evaluation of Cerebrospinal Fluid Concentration and Plasma Free Concentration As a Surrogate Measurement for Brain Free Concentration

Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Groton, Connecticut

This study was designed to evaluate the use of cerebrospinal fluid (CSF) drug concentration and plasma unbound concentration (C_u,plasma) to predict brain unbound concentration (C_u,brain). The concentration-time profiles in CSF, plasma, and brain of seven model compounds were determined after subcutaneous administration in rats. The C_u,brain was estimated from the product of total brain concentrations and unbound fractions, which were determined using brain tissue slice and brain homogenate methods. For theobromine, theophylline, caffeine, fluoxetine, and propranolol, which represent rapid brain penetration compounds with a simple diffusion mechanism, the ratios of the area under the curve of C_u,brain/C_CSF and C_u,brain/C_u,plasma were 0.27 to 1.5 and 0.29 to 2.1, respectively, using the brain slice method, and were 0.27 to 2.9 and 0.36 to 3.9, respectively, using the brain homogenate method. A P-glycoprotein substrate, CP-141938 (methoxy-3-[(2-phenyl-piperadinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide), had C_u,brain/C_CSF and C_u,brain/C_u,plasma ratios of 0.57 and 0.066, using the brain slice method, and 1.1 and 0.13, using the brain homogenate method, respectively. The slow brain-penetrating compound, N[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl-]sarcosine, had C_u,brain/C_CSF and C_u,brain/C_u,plasma ratios of 0.94 and 0.12 using the brain slice method and 0.15 and 0.018 using the brain homogenate method, respectively. Therefore, for quick brain penetration with simple diffusion mechanism compounds, C_CSF and C_u,plasma represent C_u,brain equally well; for efflux substrates or slow brain penetration compounds, C_CSF appears to be equivalent to or more accurate than C_u,plasma to represent C_u,brain. Thus, we hypothesize that C_CSF is equivalent to or better than C_u,plasma to predict C_u,brain. This hypothesis is supported by the literature data.

This article has been cited by other articles:

				X. Liu, C. Chen, and B. J. Smith Progress in Brain Penetration Evaluation in Drug Discovery and Development J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356. [Abstract] [Full Text] [PDF]

				D. W. Angus, J. A. Baker, R. Mason, and I. J. Martin The Potential Influence of CO2, as an Agent for Euthanasia, on the Pharmacokinetics of Basic Compounds in Rodents Drug Metab. Dispos., February 1, 2008; 36(2): 375 - 379. [Abstract] [Full Text] [PDF]

				M. Friden, A. Gupta, M. Antonsson, U. Bredberg, and M. Hammarlund-Udenaes In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids Drug Metab. Dispos., September 1, 2007; 35(9): 1711 - 1719. [Abstract] [Full Text] [PDF]

				K. Venkatakrishnan, E. Tseng, F. R. Nelson, H. Rollema, J. L. French, I. V. Kaplan, W. E. Horner, and M. A. Gibbs Central Nervous System Pharmacokinetics of the Mdr1 P-Glycoprotein Substrate CP-615,003: Intersite Differences and Implications for Human Receptor Occupancy Projections from Cerebrospinal Fluid Exposures Drug Metab. Dispos., August 1, 2007; 35(8): 1341 - 1349. [Abstract] [Full Text] [PDF]

				A. Yokota, S. Kimura, S. Masuda, E. Ashihara, J. Kuroda, K. Sato, Y. Kamitsuji, E. Kawata, Y. Deguchi, Y. Urasaki, et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood, January 1, 2007; 109(1): 306 - 314. [Abstract] [Full Text] [PDF]